Saniona

📍 Glostrup, Denmark🗓 Founded 2011👥 32 employees💰 Last funded May 2024
Pharmaceutical Manufacturing🌐 saniona.com
Website LinkedIn
Saniona is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona’s most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, please visit www.saniona.com (OMX: SANION).
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2011
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Saniona?
Saniona has 1 investors on record on gritt.io.
When did Saniona last raise funding?
The most recent investment in Saniona recorded on gritt.io was in May 2024.
When was Saniona founded?
Saniona was founded in 2011.
What industry is Saniona in?
Saniona operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Saniona based?
Saniona is headquartered in Glostrup, Denmark.